Comparison of screening methods in the detection of bladder cancer

Journal of Urology

Volumn 161, Issue 2, 1999, Pages 388-394

  Ramakumar, Sanjay ^a   Bhuiyan, Jalaluddin ^a   Besse, Jennifer A ^a   Roberts, Steven G ^a   Wollan, Peter C ^a   Blute, Michael L ^a   O'Kane, Dennis J ^a,b  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Bladder neoplasms; Cytology; Telomerase; Tumor markers, biological

Indexed keywords

BLADDER TUMOR ASSOCIATED ANTIGEN; BLADDER TUMOR-ASSOCIATED ANTIGEN; FIBRIN DEGRADATION PRODUCT; HEMOGLOBIN; NUCLEAR MATRIX PROTEIN 22; NUCLEAR PROTEIN; TELOMERASE; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; CYTOLOGY; FEMALE; HUMAN; MALE; MIDDLE AGED; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; URINE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HEMOGLOBINS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TELOMERASE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; URINE;

EID: 0033074324     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)61899-8     Document Type: Article

References (39)

1. Landman, J., Kavaler, E., Droller, M. and Liu, B.: Applications of telomerase in urologie oncology. World J. Urol., 15: 120, 1997.
2. Papanicolaou, G. N. and Marshall, V. F.: Urine sediment smears as a diagnostic procedure in cancers of the urinary tract. Science, 101: 519, 1945.
3. Rife, C. C., Farrow, G. M. and Utz, D. C.: Urine cytology of transitional cell neoplasms. Urol. Clin. N. Amer., 6: 599, 1979.
4. Badalament, R. A., Hermansen, D. K., Kimmel, M., Gay, H., Herr, H. W., Fair, W. R., Whitmore, W. J. and Melamed, M. R.: The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma. Cancer, 60: 1423, 1987.
5. Sarosdy, M. F., deVere, W. W., Soloway, M. S., Sheinfeld, J., Hudson, M. A., Schellhammer, P. F., Jarowenko, M. V., Adams, G. and Blumenstein, B. A.: Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J. Urol., 154: 379, 1995.
6. Van Der Poel, H. G., Van Balken, M. R., Schamhart, D. H., Peelen, P., De Reijke, T., Deburyne, F. M. J., Schalken, J. and Witjes, J. A.: Bladder wash cytology, quantitative cytology, and the qualitative BTA test in patients with superficial bladder cancer. Urology, 51: 44, 1998.
7. Leyh, H. and Mazeman, E.: Bard BTA test compared with voided urine cytology in the diagnosis of recurrent bladder cancer. Eur. Urol., 32: 425, 1997.
8. Murphy, W. M., Rivera-Ramirez, I., Medina, C. A., Wright, N. J. and Wajsman, Z.: The bladder tumor antigen (BTA) test compared to voided urine cytology in the detection of bladder neoplasms. J. Urol., 158: 2102, 1997.
9. Leyh, H., Hall, R., Mazeman, E. and Blumenstein, B. A.: Comparison of the Bard BTA test with voided urine and bladder wash cytology in the diagnosis and management of cancer of the bladder. Urology, 50: 49, 1997.
10. Ianari, A., Sternberg, C. N., Rossetti, A., Van, R. A., Deidda, A., Giannarelli, D. and Pansadoro, V.: Results of Bard BTA test in monitoring patients with a history of transitional cell cancer of the bladder. Urology, 49: 786, 1997.
11. Kinders, R., Jones, T., Root, R., Murchison, H., Bruce, C., Williams, L. and Hass, G. M.: Human bladder tumor antigen is a member of the RCA (Regulators of Complement Activation) gene family. J. Urol., part 2, 157: 28, abstract 110, 1997.
12. Kinders, R. J., Root, R., Jones, T., Bruce, C. L. and Hass, G. M.: Complement factor H-related proteins are expressed in bladder cancers. Cancer Res., 38: 29A, 1997.
13. Shelfo, S. W. and Soloway, M. S.: The role of nuclear matrix protein 22 in the detection of persistent or recurrent transitional-cell cancer of the bladder. W. J. Urol., 15: 107, 1997.
14. Carpinito, G. A., Stadler, W. M., Briggman, J. V., Chodak, G. W., Church, P. A., Lamm, D. L., Lange, P. H., Messing, E. M., Pasciak, R. M., Reservitz, G. B., Ross, R. N., Rukstalis, D. B., Sarosdy, M. F., Soloway, M. S., Thiel, R. P., Vogelzang, N. and Hayden, C. L.: Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J. Urol., 156: 1280, 1996.
15. Chen, Y.-T., Hayden, C. L., Marchand, K. J. and Makuch, R. W.: Comparison of urine collection methods for evaluating urinary nuclear matrix protein, NMP22, as a tumor marker. J. Urol., 158: 1899, 1997.
16. Nagy, J. A., Brown, L. F., Senger, D. R., Lanir, N., Van De Water, L., Dvorak, A. M. and Dvorak, H. F.: Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochem. Biophys. Acta, 948: 305, 1988.
17. Brown, L. F., Berse, B., Jackman, R. W., Tognazzi, K., Manseau, E. J., Dvorak, H. F. and Senger, D. R.: Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Amer. J. Path., 143: 1255, 1993.
18. O'Brien, T., Cranston, D., Fuggle, S., Bicknell, R. and Harris, A. L.: Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res., 55: 510, 1995.
19. Jayachandran, S., Unni, M. M., Wax, S. H. and Kim, H.: The value of urinary fibrin/fibrinogen degradation products as tumor markers in urothelial carcinoma. J. Urol., 132: 21, 1984.
20. McCabe, R. P., Lamm, D. L., Haspel, M. V., Pomato, N., Smith, K. O., Thompson, E. and Hanna, M. J.: A diagnostic-prognostic test for bladder cancer using a monoclonal antibody-based enzyme-linked immunoassay for detection of urinary fibrin-(ogen) degradation products. Cancer Res., 44: 5886, 1984.
21. Wajsman, Z., Merrin, C. E., Chu, T. M., Moore, R. H. and Murphy, G. P.: Evaluation of biological markers in bladder cancer. J. Urol., 114: 879, 1975.
22. Wajsman, Z., Williams, P. D., Greco, J. and Murphy, G. P.: Further study of fibrinogen degradation products in bladder cancer detection. Urology, 12: 659, 1978.
23. Rhyu, M. S.: Telomeres, telomerase and immortality. J. Natl. Cancer Inst., 87: 884, 1995.
24. Kyo, S., Kunimi, K., Uchibayashi, T., Namiki, M. and Inoue, M.: Telomerase activity in human urothelial tumors. Amer. J. Clin. Path., 107: 555, 1997.
25. Lin, Y., Miyamoto, H., Fujinami, K., Uemura, H., Hosaka, M., Iwasaki, Y. and Kubota, Y.: Telomerase activity in human bladder cancer. Clin. Cancer Res., 2: 929, 1996.
26. Yang, S. C., Lee, D. H., Hong, S. J., Chung, B. H. and Kim, I. Y.: Telomerase activity: a potential marker of bladder transitional cell carcinoma in bladder washes. Yonsei Med. J., 38: 155, 1997.
27. Kinoshita, H., Ogawa, O., Kakehi, Y., Mishina, M., Mitsumori, K., Itoh, N., Yamada, H., Terachi, T. and Yoshida, O.: Detection of telomerase activity in exfoliated cells in urine from patients with bladder cancer. J. Natl. Cancer Inst., 89: 724, 1997.
28. Yoshida, K., Sugino, T., Tahara, H., Woodman, A., Bolodeoku, J., Nargund, V., Fellows, G., Goodison, S., Tahara, E. and Tarin, D.: Telomerase activity in bladder carcinoma and its implication for noninvasive diagnosis by detection of exfoliated cancer cells in urine. Cancer, 79: 362, 1997.
29. Koss, L. G.: Tumors of the urinary tract and prostate in urinary sediment. In: Diagnostic Cytology and Its Histopathologic Bases, 4th ed. Philadelphia: J. B. Lippincott Co., vol. 2, chapt. 23, pp. 951-963, 1992.
30. Sarosdy, M. F., Hudson, M. A., Ellis, W. J., Soloway, M. S., deVere, W. R., Sheinfeld, J., Jarowenko, M. V., Schellhammer, P. F., Schervish, E. W., Patel, J. V., Chodak, G. W., Lamm, D. L., Johnson, R. D., Henderson, M., Adams, G., Blumenstein, B. A., Thoelke, K R., Pfalzgraf, R. D., Murchison, H. A. and Brunelle, S. L.: Improved detection of recurrent bladder cancer using the Bard BTA stat Test. Urology, 50: 349, 1997.
31. Stampfer, D. S., Carpinito, G. A., Rodriguez-Villanueva, J., Willsey, L. W., Dinney, C., Grossman, H. B., Fritsche, H. A. and McDougal, W. S.: Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J. Urol., 159: 394, 1998.
32. Kim, N. W., Piatyszek, M. A., Prowse, K R., Harley, C. B., West, M. D., Ho, P. L., Coviello, G. M., Wright, W. E., Weinrich, S. L. and Shay, J. W.: Specific association of human telomerase activity with immortal cells and cancer. Science, 266: 2011, 1994.
33. Hosmer, D. W. and Lemeshow, S.: Applied Logistic Regression, 1st ed. New York: John Wiley and Sons, Inc., 1989.
34. Landis, S. H., Murray, T., Bolden, S. and Wingo, P. A.: Cancer statistics, 1998. Cancer J. Clin., 48: 6, 1998.
35. Ellis, W. J., Blumenstein, B., Ishak, L. M., Enfield, D. L. and the Multi Center Study Group: Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. Urology, 50: 882, 1997.
36. Schmetter, B. S., Habicht, K. K., Lamm, D. L., Morales, A., Bander, N. H., Grossman, H. B., Hanna, M. J., Silberman, S. R. and Butman, B. T.: A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer. J. Urol., 158: 801, 1997.
37. Johnston, B., Morales, A., Emerson, L. and Lundie, M.: Rapid detection of bladder cancer: a comparative study of point of care tests. J. Urol., 158: 2098, 1997.
38. Kavaler, E., Landman, J., Chang, Y., Droller, M. and Liu, B.: Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity. Cancer, 82: 708, 1998.
39. Sidransky, D.: Nucleic acid-based methods for the detection of cancer. Science, 278: 1054, 1997.